Background: We evaluated the changes in the levels of soluble biomarkers of inflammation and coagulation and T-cell activation among participants of AIDS Clinical Trials Group Study A5217 who were started on antiretroviral therapy (ART) within the first 6 months of HIV infection.
INTRODUCTION
Chronic, treated HIV-1 infection has been associated with an increased risk of chronic diseases, such as cardiovascular disease and HIV-associated malignancies. 1 This increased risk is hypothesized to be the result of persistent immune activation and increased systemic inflammation. Although virologic suppression on antiretroviral therapy (ART) leads to a decrease in several biomarkers of immune activation and inflammation to levels observed in HIVseronegative controls, levels of other inflammatory biomarkers remain elevated. 2 Indeed, these increased levels of soluble inflammatory biomarkers during effective ART have been shown to predict non-AIDS-defining adverse outcomes. 3 Initiation of ART during early HIV-1 infection has been proposed as a possible strategy to prevent persistent immune dysfunction despite virologic suppression. However, studies evaluating the effect of initiating ART in early infection on biomarkers of immune activation and inflammation have shown varying results. 4 Therefore, we evaluated changes in the levels of soluble biomarkers of inflammation, monocyte activation, and coagulation among individuals who started ART within 6 months of HIV acquisition in the AIDS Clinical Trials Group Study A5217 (The Setpoint Study). 5 In addition, we compared levels of these biomarkers and levels of T-cell activation among these individuals at study entry, before ART, and during a period of treatment interruption.
METHODS
AIDS Clinical Trials Group Study A5217 is a 96-week, open-label study in which recently HIV-1-infected adults (defined as a nonreactive detuned HIV-1 antibody test or documented seroconversion) were randomized to either receive 36 weeks of ART followed by treatment discontinuation (immediate treatment with boosted lopinavir, tenofovir, and emtricitabine; IT group) or followed off-treatment (delayed treatment; DT group) until study-defined criteria were reached and ART was restarted. 5 The study sought to compare virologic set point 36 weeks after treatment discontinuation in the IT group with the virologic set point of the DT group 72 weeks into the study. Of the 66 A5217 study participants in the IT group, 32 participants with available plasma and peripheral blood mononuclear cell samples and the following clinical data were included in this immunologic analysis: HIV-1 RNA and CD4 + T-cell counts available at weeks 0, 36 (obtained before treatment interruption), and 72 (36 weeks after starting treatment interruption). Samples from the time points were thawed and analyzed in batches. Plasma concentrations of D-dimer (coagulation biomarker) and soluble CD14 (sCD14; monocyte activation marker) were quantified using the D-dimer enzymelinked immunosorbent assay (ELISA) kit (American Diagnostica, Lexington, MA) and sCD14 ELISA Quantikine kit (R&D Systems, Minneapolis, MN), respectively, per manufacturer's instructions. Duplicates of 20% of the samples were included in each ELISA plate, and results were analyzed using Dynex Plate Reader (Dynex Technologies, Chantilly, VA). Plasma concentrations of C-reactive protein (CRP; inflammatory biomarker) were quantified using the Single-plex CRP Luminex kit (Invitrogen, Grand Island, NY) and analyzed using the BioPlex Multiple system platform (Bio-Rad, Hercules, CA). For the assessment of T-cell activation, thawed peripheral blood mononuclear cells were stained with the following monoclonal antibodies: anti-CD3 (APC-H7), anti-CD4 (V450), anti-CD8 (PE-Cy7), anti-HLA-DR (PE), and anti-CD38 (APC). Specimens were analyzed within 24 hours of staining using an LSR Fortessa flow cytometer (BD Biosciences, San Jose, CA). Changes in the levels of soluble markers and T-cell activation were analyzed using Wilcoxon signed rank test, whereas differences in demographic data were analyzed using Wilcoxon rank sum test. Spearman correlations were computed to explore associations between the immunologic parameters. P values of ,0.05 were considered significant. Table 1 shows the baseline demographics of the 66 participants randomized to the IT arm, and the 32 participants included in this analysis. Of these 32 study participants, 84% were male subjects and 81% were white. They were older than the other participants in the IT group (median age of 39 years vs 27; P = 0.028, Wilcoxon rank sum test). The median CD4 + T-cell count was 494 cells per cubic millimeter at week 0, 663.5 cells per cubic millimeter at week 36 (vs week 0; P , 0.001), and 539 cells per cubic millimeter at week 72 (vs week 0; P = 0.092). The median HIV-1 RNA level at week 0 was 4.37 log 10 copies per milliliter, whereas the median at week 72 was 4.17 log 10 copies per milliliter (P = 0.073). The median duration of viral suppression (,50 copies/mL) is 26 weeks.
RESULTS

Demographics
Changes in Soluble Markers and T-Cell Activation
We evaluated changes in the levels of CRP, sCD14, and D-dimer 36 weeks after starting ART and after 36 weeks of treatment interruption (Figs. 1A-C) . At week 36, only the plasma levels of D-dimer were significantly lower compared with pre-ART levels (from a median of 2.28 log 10 ng/mL to 2.19; P = 0.031). Despite virologic suppression on ART, levels of CRP and sCD14 remained similar to baseline levels. At week 72 (36 weeks after ART interruption), plasma levels of D-dimer and sCD14 biomarkers were similar to baseline, whereas there was a trend toward higher levels of CRP. We evaluated whether the plasma levels of biomarkers correlated with each other and with the CD4 + T-cell counts at the time of virologic suppression (week 36). There was a trend toward a positive correlation between CRP and D-dimer levels (r = 0.34; P = 0.066; data not shown). However, there were no observed correlations between CD4 + T-cell counts and levels of the 3 soluble markers at week 36.
Given the availability of samples, we were only able to compare levels of T-cell activation (defined as the frequency of CD4 and CD8 + T cells that coexpress HLA-DR and CD38) at the week 0 time point and at week 72 (Figs. 1D-E) . Although levels of CD4 + T-cell activation were similar between the 2 time points, levels of CD8 + T-cell activation were significantly lower at week 72 (from a median of 35.3% at week 0% to 28.9% at week 72; P = 0.004).
Association of Baseline CD4 + T-Cell Counts and HIV-1 RNA With Soluble Biomarker Levels
We then assessed whether baseline levels of CD4 + T-cell count and plasma HIV-1 RNA were predictive of the levels of soluble biomarkers during virologic suppression (week 36). Baseline CD4 + T-cell count tended to modestly correlate with the levels of D-dimer during viral suppression (r = 0.35; P = 0.058) but did not correlate with levels of sCD14 and CRP (Supplemental Digital Content, Fig. 1 , http://links.lww.com/QAI/A976). On the other hand, baseline HIV-1 RNA was not predictive of the levels in any of the soluble biomarkers at week 36.
DISCUSSION
Early ART is hypothesized to be an important strategy in preventing persistent HIV-associated inflammation elevation despite virologic suppression on ART. Indeed, initiation of ART during early infection has been associated with normalization of CD4 + T-cell counts within the first year, lower levels of immune activation, and a smaller HIV DNA and RNA reservoir size. 6, 7 Given that soluble markers of inflammation and coagulation have been associated with non-AIDS adverse outcomes during virologic suppression, 3 we evaluated changes in the levels of soluble biomarkers in A5217 participants who were randomized to immediate ART, that is, within the first 6 months of HIV infection. Ddimer and CRP have both been associated with mortality in HIV(+) individuals. 8 D-dimer has been independently associated with endothelial dysfunction 9 whereas sCD14 has been associated with cardiovascular disease in treated infection 10 among treated HIV(+) individuals. Levels of Ddimer significantly decreased with ART, which is consistent with findings from the Strategies for Management of Antiretroviral Therapy (SMART) Trial. 11 This is also consistent with findings from another early treatment study, the SPARTAC trial, 12 and supports the importance of early ART especially because D-dimer levels are associated with serious non-AIDS conditions or death in those with suppressed viremia. 13 However, even with early ART and with a median virologic suppression of 26 weeks, the levels of sCD14 and CRP did not significantly change at week 36. These findings are consistent with results from 2 other studies evaluating inflammatory biomarkers in the setting of ART-induced viral suppression 2,14 but in contrast to another study that showed a decline in these markers after ART initiation. 15 Our findings suggest that viremia alone is not responsible for persistent monocyte activation and inflammation during treatment. It is likely that damage to the immune system during the acute stages of HIV infection may be responsible for the persistent elevation of these markers despite viral suppression. Given the limitations with sample availability, we were unable to evaluate levels of T-cell activation during viral suppression. Results from other studies have shown that these levels (measured by % coexpression of HLA-DR and CD38 on T cells or by levels of soluble CD27) decrease upon start of ART. 2, 15 Although the study population in these 2 studies include individuals who started ART during chronic HIV infection, we believe that the dynamics of T-cell activation levels in our population will be the same. It is important to note that A5217 did not include participants who were treated during acute infection, and studies evaluating changes in inflammatory biomarker levels in this population will be important in fully evaluating the impact of early treatment on the levels of chronic inflammation during viral suppression.
With treatment interruption, levels of all the soluble markers returned to pre-ART levels, showing that the initiation of ART in the IT group did not impact any of the soluble markers after ART was interrupted. Although we expected levels of T-cell activation to return to pre-ART baseline upon treatment interruption, we observed significantly lower levels of week 72 CD8 + T-cell activation compared with pre-ART levels, which suggests a benefit of early treatment especially given the association of T-cell activation with disease progression. 16 However, this was counteracted by the lack of change in the levels of the soluble biomarkers, specifically sCD14, which has been associated with higher hazards of long-term mortality and serious non-AIDS events. 17, 18 Our study has several limitations. Because we did not include individuals diagnosed during acute infection, we cannot fully evaluate the impact of early ART in levels of inflammation and immune activation. Also, participants in the study were virally suppressed for only a median of 26 weeks. Thus, it is possible that further reductions in the levels of CRP and sCD14 may be evident with prolonged viral suppression. It is also possible that the older age in our study population may have affected some of our results, although we do not believe that the difference could have significantly altered the results of the study. Given that the study was conducted in 2005, it is important to note that the ART regimen used in this study, specifically the protease inhibitor (PI), is no longer recommended as the initial line of therapy. It is possible that levels of these soluble markers may be influenced by the difference in PI choice given in vitro findings showing differences in the effect of different PIs on endothelial cells, including their secretion of inflammatory markers. 19 In summary, in our study population of individuals who were diagnosed within the first 6 months of infection, but not during acute infection, initiation of ART has some beneficial effects; however, immune damage occurring during the initial weeks of HIV infection likely leads to residual immune dysfunction that does not seem to be reversed with shortterm treatment.
